Colonoscopy

In a video exclusive, Craig Munroe, MD, discusses how recent revisions to quality indicators for colonoscopy from ACG and ASGE may improve patient outcomes by raising the standards of the procedure.

The FDA approved Exact Sciences’ Cologuard Plus multitarget stool DNA test to screen adults aged 45 years or older at average risk for colorectal cancer, according to a company press release.

Delays in cancer registration may have underestimated 10-year colorectal cancer risk reductions by up to 75% in the NordICC trial, with researchers warning that study estimates on screening colonoscopy should be “interpreted with caution.”

Although training primary care providers in shared decision-making did not significantly improve colorectal cancer concordance or screening rates in older adults, at least 5 minutes of discussion with a PCP may benefit some, data showed.

An AI-assisted endoscopy module increased adenoma detection, including sessile serrated lesions, during colonoscopy and is recommended in routine practice to reduce incidence of post-procedure colorectal cancer, according to researchers.

As the launch of UnitedHealthcare’s Gold Card program approaches, the AGA continues to urge the insurer to reconsider implementation of a program that could affect various gastrointestinal procedures and “threaten patient health.”

Revised quality indicators released by the ACG and ASGE highlight the importance of adenoma and sessile serrated lesion detection rates as well as adequate bowel preparation for improving the technical performance of colonoscopy.

The ACG and ASGE have released an updated quality indicators document, intended to serve as a framework to improve performance of endoscopic procedures.

Autonomous AI exhibited “noninferior accuracy” for optical diagnosis of diminutive colorectal polyps vs. AI-assisted endoscopists, yet surpassed endoscopist accuracy in later pathology-based surveillance intervals, according to researchers.

AI has already made its mark in gastroenterology as a tool for detecting gastrointestinal lesions, adenomas and inflammatory bowel disease. However, its next phase of evolution might seem the most unlikely: Aiding colonoscopy preparation.